ANTI-SARS-CoV-2 ELECSYS/e 411 200T ROCHE
Elecsys Anti‑SARS‑CoV‑2 is an immunoassay for the in vitro qualitative detection of antibodies (including IgG) to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2) in human serum and plasma. The test is intended as an aid in the determination of the immune reaction to SARS‑CoV‑2
The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.
Sandwich principle. »Total duration of assay: 18 minutes.
▪ 1st incubation: 20 µL of sample, biotinylated SARS‑CoV‑2‑specific recombinant antigen and SARS‑CoV‑2‑specific recombinant antigen labeled with a ruthenium complexa) form a sandwich complex.
▪ 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.
▪ The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M. Application of a voltage to the electrode then induces
chemiluminescent emission which is measured by a photomultiplier.
▪ Results are determined automatically by the software by comparing the electrochemiluminescence signal obtained from the reaction product of the sample with the signal of the cutoff value previously obtained by calibration.
Each package contains 200 assays.